Pathogenic role and diagnostic utility of interferon-α in histiocytic necrotizing lymphadenitis.

Histiocytic necrotizing lymphadenitis Interferon stimulated gene Interferon-α Kikuchi–Fujimoto disease Plasmacytoid dendritic cell Subacute necrotizing lymphadenitis

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
18 Jul 2024
Historique:
received: 15 04 2024
revised: 13 06 2024
accepted: 16 07 2024
pubmed: 21 7 2024
medline: 21 7 2024
entrez: 20 7 2024
Statut: aheadofprint

Résumé

Histiocytic necrotizing lymphadenitis (HNL) is an inflammatory disease of unknown etiology clinically characterized by painful lymphadenopathy. This study aimed to investigate the role of interferon (IFN)-α in the pathogenesis of HNL and the clinical significance of serum IFN-α levels for the diagnosis and monitoring of HNL disease activity. This study enrolled 47 patients with HNL and 43 patients with other inflammatory diseases that require HNL differentiation including malignant lymphoma (ML), bacterial lymphadenitis, and Kawasaki disease. Expression of IFN-stimulated genes (ISGs) and MX1 in the lymph nodes was measured by real-time quantitative reverse transcription polymerase chain reaction and immunofluorescence staining, respectively. Enzyme-linked immunosorbent assay was used to quantify serum cytokine levels. The results were compared with the clinical features and disease course of HNL. Patients with HNL had a significantly elevated ISG expression in the lymph nodes compared with those with ML. MX1 and CD123, a specific marker of plasmacytoid dendritic cells (pDCs), were colocalized. In patients with HNL, serum IFN-α levels were significantly elevated and positively correlated with disease activity. The serum IFN-α level cutoff value for differentiating HNL from other diseases was 11.5 pg/mL. IFN-α overproduction from pDCs may play a critical role in HNL pathogenesis. The serum IFN-α level may be a valuable biomarker for the diagnosis and monitoring of disease activity in patients with HNL.

Identifiants

pubmed: 39032847
pii: S1521-6616(24)00433-9
doi: 10.1016/j.clim.2024.110324
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110324

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest All the authors declare that they have no relevant conflicts of interest.

Auteurs

Shuya Kaneko (S)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Asami Shimbo (A)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Hitoshi Irabu (H)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Maho Hatano (M)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Kei Takasawa (K)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Takahiro Kamiya (T)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Keiji Akamine (K)

Department of Nephrology and Rheumatology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Takayuki Tanaka (T)

Department of Pediatrics, Japanese Red Cross Otsu Hospital, Shiga, Japan.

Toshinori Minato (T)

Department of Pediatrics, Toyooka Hospital, Hyogo, Japan.

Makoto Ono (M)

Department of Pediatrics, Chiba Kaihin Municipal Hospital, Chiba, Japan.

Koji Yokoyama (K)

Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Atsuko Arisaka (A)

Department of Pediatrics, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.

Takahiro Yasumi (T)

Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Kazuyuki Ueno (K)

Department of Pediatrics, Toyama Prefectural Central Hospital, Toyama, Japan.

Shuhei Fujita (S)

Department of Pediatrics, Toyama Prefectural Central Hospital, Toyama, Japan.

Yumi Tanaka (Y)

Department of Pediatrics, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Daisuke Hayashi (D)

Department of Pediatrics, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Hiroki Nishikawa (H)

Department of Pediatrics, Nara Prefecture General Medical Center, Nara, Japan.

Yuji Fujita (Y)

Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.

Yuki Yuza (Y)

Department of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Masaaki Mori (M)

Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Tomohiro Morio (T)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Masaki Shimizu (M)

Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: mshimizu.ped@tmd.ac.jp.

Classifications MeSH